(UroToday.com) In a plenary presentation in the Navigating Uncertain Times in Muscle-Invasive and Advanced Bladder Cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Dr. Hoskin discussed uncertainties in trimodality therapy (TMT) for muscle invasive bladder cancer (MIBC).